Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Product: Frozen Breaded Shrimp Patties, Frozen Tempura Shrimp Roll Issue: Food - Allergen - Egg           Food - Allergen - Soy           Food - Allergen - Milk Distribution: British Columbia         ...

As interest in longevity science continues to explode among consumers, GeeVida Health, in collaboration with Life Time , is hosting a holistic health event Saturday, June 14, 2025 at the UC Irvine ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...